Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 August 2023Published: 26 March 2020
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 27 February 2013
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 15 March 2012
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 23 September 2015
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 2 July 2021Published: 23 May 2012
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)Product type:GuidanceProgramme:NICE guidelineLast updated: 13 August 2019Published: 21 March 2018
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 June 2015
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 December 2014
The geko device for reducing the risk of venous thromboembolism (HTG344)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 June 2014
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2013
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 July 2012
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 January 2012
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 April 2009
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery (TA157)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 September 2008
Thromboaspiration for Intermediate risk Pulmonary EmbolismStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Mechanical Thrombectomy for PEStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing strokeStatus:In development | In consultationProgramme:Interventional procedures guidanceConsultation end date: 19 February 2026Expected publication date: TBC
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolismStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC